Delving into the Latest Updates on Zuclopenthixol Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol, 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol, Chlorpenthixol

+ [5]

Target

D1 receptor x D2 receptor

Action

antagonists

Mechanism

D1 receptor antagonists(Dopamine D1 receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)

Therapeutic Areas

Nervous System Diseases

Active Indication

Bipolar DisorderSchizophrenia

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1962),

Bipolar DisorderSchizophrenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC22H26Cl2N2OS

InChIKeyBUVIOIVVDWLSMQ-CVIBNLPVSA-N

CAS Registry58045-23-1

View All Structures (2)

The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency.
The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.

Start Date01 Apr 2012

Sponsor / Collaborator

Canadian Institutes of Health Research

EUCTR2008-000584-42-DE

/ Not yet recruitingNot ApplicableIIT

Effekte von Zuclopenthixol auf aggressives Verhalten bei Kindern und Jugendlichen mit einer geistigen oder Lernbehinderung (unterdurchschnittlichen Intelligenz)

Start Date06 Aug 2008

Sponsor / Collaborator-

100 Clinical Results associated with Zuclopenthixol Hydrochloride

Login to view more data

100 Translational Medicine associated with Zuclopenthixol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Zuclopenthixol Hydrochloride

Login to view more data

550

Literatures (Medical) associated with Zuclopenthixol Hydrochloride

01 Mar 2025·Journal of Affective Disorders

Addition of long-acting injectable antipsychotics during manic episodes in bipolar disorder: A retrospective analysis of rehospitalizations

Article

Author: Chan, Chia-Hsiang ; Huang, Shang-Chien ; Tien, Yun ; Huang, Hsiang-Ping ; Wang, Vincent Xi-Yu

INTRODUCTIONBipolar disorder (BD) often necessitates hospitalization, especially during manic episodes. Long-acting injectable antipsychotics (LAIs) are theorized to enhance treatment adherence and decrease rehospitalization rates compared to oral medications. This study aimed to evaluate the real-world effectiveness of LAIs in reducing rehospitalizations among BD patients admitted for bipolar mania.METHODSWe conducted a retrospective cohort study using data from a tertiary psychiatry hospital in Taiwan spanning January 1st, 2006, to December 31st, 2017. We analyzed 2212 hospitalizations among 945 patients with bipolar mania. A mixed-effects Cox regression model compared rehospitalization hazards between LAIs, mood stabilizer plus oral antipsychotic (MS + OAP), and mood stabilizer only (MS) groups. Sensitivity analyses assessed robustness across various subgroup criteria.RESULTSLAI treatment significantly reduced the hazard of rehospitalization within one year post-discharge compared to MS + OAP (HR = 2.29, 95 % CI = 1.56-3.36) and MS alone (HR = 2.66, 95 % CI = 1.68-4.21). This effect was consistent across different rehospitalization types-all-cause, bipolar disorder-specific, and bipolar mania-specific. Each additional previous hospitalization was associated with higher hazard of rehospitalization across the three rehospitalization types. Sensitivity analyses suggested LAIs' efficacy in manic episodes with and without psychotic symptoms and for patients with frequent hospitalizations. The LAIs included in the analysis are haloperidol, risperidone, fluphenazine, flupentixol, and zuclopenthixol.CONCLUSIONOur findings suggest that the addition of LAIs for bipolar mania during acute inpatient treatment is associated with reduced rehospitalizations, particularly among patients with recurrent hospitalizations, making it a valuable option. However, the lack of outpatient prescription data limits our ability to further substantiate this concept, warranting future research.

01 Jul 2024·International Clinical Psychopharmacology

Sociodemographic and clinical factors associated with prescription of first- versus second-generation long-acting antipsychotics in incarcerated adult males

Article

Author: Caldiroli, Alice ; Surace, Teresa ; Cova, Francesca ; Buoli, Massimiliano ; Clerici, Massimo ; Di Forti, Carla Laura ; Capuzzi, Enrico

Information on patterns of prescription of long-acting injection (LAI) antipsychotics among people who are incarcerated is lacking. Therefore, we aimed to evaluate prescribing rates for first-generation antipsychotic (FGA)-LAI versus second-generation antipsychotic (SGA)-LAI and to identify the factors associated with the prescription of one of the two classes of LAI. A cross-sectional study was conducted among incarcerated adult males hosted in Monza detention center between January 2013 and April 2023. Socio-demographic and clinical data were retrospectively collected. Descriptive and univariate statistics as well as logistic regression analyses were performed. Data were available for 135 consecutive incarcerated adult males with different mental disorders who received a LAI as part of their treatment. 75.6% of our sample was treated with FGA-LAIs, with haloperidol as the most commonly prescribed drug, followed by zuclopentixol and aripiprazole. Diagnosis of bipolar disorder and concomitant administration of antidepressants were statistically significant predictors of SGA-LAI prescription. Some patients’ characteristics may influence prescription patterns in prison. Further longitudinal studies with larger samples should confirm these findings.

30 Apr 2024·Schizophrenia Bulletin

Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report

Article

Author: Banzato, Claudio Eduardo Muller ; Barros, Felipe Mendonça Rocha ; dos Santos Junior, Amilton ; Tolentino, Arthur Cardoso ; Dalgalarrondo, Paulo ; Marques, Lais Soares Ker ; Schlittler, Leandro Xavier de Camargo ; Oliveira, Karina Diniz ; Barnes, Lucas Luchesi

AbstractIntroductionClozapine, a second-generation antipsychotic (SGA), is considered the gold standard medication to treat patients with treatment-resistant schizophrenia (TRS). Despite its efficacy, clozapine is associated with adverse effects, notably neutropenia and agranulocytosis. Other hematological adverse effects are less common. Severe anemia is a rare adverse effect seldom reported in the literature and is typically associated with pure red cell aplasia (PRCA). Nevertheless, the benefits of clozapine in managing TRS make rechallenge a reasonable option.Case ReportWe present the case of a 35-year-old man with TRS, resistant to previous antipsychotics, who experienced severe anemia during clozapine treatment. An investigation for clozapine-induced anemia revealed PRCA on myelogram. After discontinuing clozapine, the patient’s hemoglobin levels recovered. Subsequent treatments with olanzapine, zuclopenthixol, and aripiprazole proved ineffective, leading us to consider a clozapine rechallenge. The rechallenge, monitored for 58 days, resulted in improved psychiatric symptoms and stable hemoglobin levels. The patient remained stable during 6 months of follow-up, with no hematological changes.DiscussionPRCA is a very rare adverse effect of clozapine. The cause of drug-induced PRCA is still unknown; for clozapine, there are no studies. Rechallenge after a severe and rare adverse effect is a complex decision. This case is the first to report a successful clozapine rechallenge following severe anemia without other blood dyscrasias, emphasizing the imperative need for close monitoring during the rechallenge process. Further study is warranted to understand the predictive factors for a successful outcome in clozapine rechallenges.

100 Deals associated with Zuclopenthixol Hydrochloride

Login to view more data